GSK 新闻通稿
GSK中国今天宣布，在国家卫生和计划生育委员会的指导下，GSK与中华预防医学会（CPMA）缔结战略合作伙伴关系，在为期3年的战略合作框架下，双方将携手应对中国公共卫生领域主要挑战，包括公共卫生与预防医学领域人才队伍培养，以及艾滋病、病毒性肝炎、宫颈癌等重大疾病预防教育，为加快推进健康中国建设作出贡献。
近期，中国政府颁发了新修订的疫苗流通和预防接种管理条例，进一步提升疫苗接种的质量和安全性。GSK中国全力支持该新政的实施，并将与中华预防医学会合作，通过公众的预防教育和预防接种人员相关能力的培训等，助力中国医疗卫生体系的不断完善。在未来3年内，该合作下的“全国预防接种服务与管理培训计划”预计将覆盖4000余名全国基层预防接种人员。
艾滋病、宫颈癌、病毒性肝炎都是中国主要的公共卫生问题。宫颈癌是中国15岁至44岁女性中的第二大高发癌症，每年约有13万新发病例。每年, 中国的宫颈癌病例占全球的28%以上。根据国家卫生计生委的报告，仅在2014年，中国新报告的艾滋病感染者和病人就达到10.4万例，比2013年增加14.8%左右，尤其值得关注的是，24岁及以下青少年感染者的比例正在逐年上升。乙型肝炎是中国公共卫生领域的一个首要问题，近2000万名乙型肝炎患者尚未得到有效治疗。
中华预防医学会会长王陇德院士说，“目前，中国仍然面临多重疾病威胁并存、多种健康影响因素交织的复杂局面，迫切需要从健康服务供给侧和需求侧两端发力，从个人、行业和社会三个层面统筹做好健康服务工作。企业和社会组织作为社会公共治理体系的组成部分，任重道远。GSK与中华预防医学会作为健康领域的企业和社会组织的一分子，在新形势下，希望继续传承和发扬合作共赢的传统，把合作优势转化为促进公众健康的动力，为公众创造更多实实在在的成果。”
中华预防医学会会长王陇德院士
GSK全球首席执行官安伟杰爵士表示，“GSK致力于对中国的承诺，并将业务聚焦于能为中国病患和人群带来切实改变的疾病领域。我们要确保我们的战略能最大程度支持中国和中国人民的社会、经济和发展需求。与中华预防医学会的战略合作是GSK大力支持中国公共卫生事业的又一实质性举措。”
GSK全球首席执行官安伟杰爵士
GSK和中华预防医学会的合作可以追溯到10余年前，双方已经达成了互相尊重、合作共赢的伙伴关系。近年，GSK也与中华预防医学会紧密合作，2015-2016连续两年支持世界肝炎日系列活动，助力中国政府的肝病防治举措。
GSK践行“立足中国、携手中国、服务中国”承诺的例证还包括：
2016年7月，GSK宣布预防女性宫颈癌的疫苗希瑞适®被批准在中国上市。
2016年6月，GSK宣布GSK传染病和公共卫生研究所与清华大学缔结战略合作备忘录，共同致力于应对全球公共卫生的挑战。
2016年6月， 艾滋病治疗创新药物特威凯®正式在中国上市。
2016年5月，GSK中国宣布降低抗慢性乙肝治疗一线药物在中国的价格，降幅高达67%。这一宣布基于国家卫生计生委和其他相关部委公布的首批国家药品价格谈判结果。
2016年3月，GSK宣布在中国北京成立传染病和公共卫生研究所，开展艾滋病预防和耐多药结核药物的研发活动。
自2015 年9月，GSK与国家卫生计生委合作开展涵盖13,000名乙肝和慢性阻塞性肺病（COPD）的基层医生培训项目。
2015年7月，GSK宣布与上海迪赛诺公司合作，支持艾滋病治疗新药特威凯®原料药在华生产。
自2015年5月， GSK中国实施新的商业运营模式，为患者受益而积极提升与医疗专业人士进行学术交流的质量。
关于GSK：
GSK是全球领先的、以研发为基础的药品和保健品公司，致力于让人们能够做到更多、感觉更舒适、生活更长久，从而提高人类的生活质量。更多信息请浏览www.gsk.com。
关于GSK对中国的承诺：
我们是一家以科学为导向的全球医药保健公司，研发并生产多种类的疫苗、消费保健品和药物。我们所做的一切皆以人为核心，致力于将质量更高、效果更好的产品带给有需要的人。在中国，以及在全世界，我们的使命是帮助人们做到更多，感觉更舒适，生活更长久。不断创新产品，提高产品可及性，这对完成我们的使命至关重要，由此我们才能协助建立更健康、更具活力的社会。立足中国，携手中国，服务中国，是我们不变的承诺。
GSK strengthens commitment to address major public health challenges in China
GSK press release
GSK China today announced it will form a strategic partnership with China Preventive Medicine Association (CPMA) under the guidance of National Health and Family Planning Commission of China (NHFPC). Within a three-year strategic collaboration framework, GSK China and CPMA will work closely together to address major public health challenges in China, including training to enhance capability building of prevenetion and vaccination workers in China, as well as disease awareness education to prevent major diseases such HIV, HBV and cervical cancer, to contribute to the speedy implementation of “Healthy China” Campaign.
Recenly, the Chinese government issued new regulations on the administration of vaccines distribution to further improve the quality and safety of vaccination in the country. GSK China fully supports the implementation of the new regulations, and will work together with CMPA on disease prevention education, as well as training of prevention and vaccination workers in the network of Disease Control Centre of China (CDC) to further enhance their capabilities, aiming to play an active role in the continuous improvement of China’s healthcare infrastructure. Over the next three years, the training programme under this partnership will cover over 4,000 primary prevention and vaccination workers across the country.
HIV, HBV and cervical cancer are all major public health threats in China. Cervical cancer is the second most common cancer in women aged between 15 to 44 years in China, with an estimated 130,000 new cases each year. Every year, China accounts for more than 28% of the world’s cervical cancer cases. Reported by the National Health & Family Planning Commission (NHFPC), in 2014 alone, 104,000 new cases of HIV infection were reported in China, a 14.8% increase over previous year. Moreover, the percentage of patients 24 years and younger living with HIV has been on the rise year on year. Hepatitis B has been identified as a healthcare priority in China, with approximately 20 million sufferers across the country remaining untreated.
Wang Longde, Academician, President of the China Preventive Medicine Association (CPMA) said that China is now faced with a complex situation, on one hand we are facing the threats of multiple diseases, with complications arising from multiple health-impacting factors on the other. This situation, he said, is in urgent need of being addressed, with individuals, the industry and society all playing a role to tackle these challenges in a coordinated fashion. He said, “Under these new circumstances, GSK and CPMA, one a healthcare industry player and the other a social organisation, hope to carry forward and build on a history of win-win cooperation, and leverage our cooperative strengths to create a momentum towards better public health, bringing greater tangible benefits to the public.”
Wang Longde, Academician, President of the China Preventive Medicine Association (CPMA)
GSK Chief Executive Officer Sir Andrew Witty said, “GSK is committed to China, and we’re focusing our commitment on the therapeutic areas where we can make a real difference for the patients and people of China. This means how we can best align our strategy to the social, economic and development needs of China and its people. I see the strategic partnership with CPMA as an opportunity for us to deliver on this promise.”
Sir Andrew Witty, Chief Executive Officer, GSK
The collaboration of GSK and CPMA could be traced back to over 10 years ago, and both parties have established mutual respect and a win-win relationship. Recently, GSK worked closely with CPMA on the World Hepatitis Day public education campaign in 2015 and 2016, to contribute to the HBV prevention and treatment efforts led by the Chinese government.
As part of the ‘in China, with China, for China’ strategy, GSK China has already:
Announced the approval of Cervarix in China to help protect women from cervical cancer in July 2016.
Announced a Memorandum of Understanding between the GSK Institute for Infectious Diseases and Public Health and Tsinghua University to tackle global public health challenges in June 2016.
Launched Tivicay, an innovative HIV drug, in June 2016.
Participated in the national price negotiation pilot and announced a price reduction of our first line chronic hepatitis B treatment, Viread, by up to 67% in May 2016.
Announced a Beijing-based Institute for Infectious Disease and Public Health to conduct local development programs for pivotal HIV and TB R&D assets in March 2016.
Partnered with the National Health and Family Planning Commission on a multi-year program to fund independent training programs in Hepatitis and COPD for over 13,000 healthcare professionals from September 2015.
Formalised a partnership with Shanghai-based Desano Pharmaceuticals to locally manufacture the Active Pharmaceutical Ingredient for Tivicay (dolutegravir) in July 2015.
Transformed our commercial operating model to actively contribute to improving the quality of scientific exchanges with healthcare professionals for the benefit of patients since May 2015.
GSK：
One of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
GSK commitment to China
We are a science-led global healthcare company. We research, develop and manufacture a wide range of medicines, vaccines and consumer healthcare products. People are at the heart of what we do. We strive to bring high quality, high performing products to everyone who needs them. Creating innovative products and improving access to them is critical to our mission, allowing us to help build stronger, healthier communities. In China, and around the world, we are on a mission to help peopledo more, feel better, live longer. We are in China, with China, for China, and our commitment remains unwavering.